Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
Hum Vaccin Immunother. 2018 01 02; 14(1):85-94.HV

Abstract

BACKGROUND

Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) can cause invasive pneumococcal diseases (IPD), pneumonia, and acute otitis media (AOM). Both the 10-valent pneumococcal NTHi protein D conjugate vaccine (PHiD-CV) and the 13-valent pneumococcal conjugate vaccine (PCV-13) are included in the National Immunization Program for infants in Korea. This study aimed to evaluate the cost-effectiveness of the 3+1 schedule of PHiD-CV versus that of PCV-13 for National Immunization Program in Korea.

METHODS

A published Markov model was adapted to evaluate the cost-effectiveness of vaccinating the 2012 birth cohort with PHiD-CV vs. PCV-13 from the Korean government perspective over 10 y. Best available published data were used for epidemiology, vaccine efficacy and disutilities. Data on incidence and direct medical costs were taken from the national insurance claims database. Sensitivity analyses were conducted to explore the robustness of the results.

RESULTS

PHiD-CV was projected to prevent an additional 195,262 cases of pneumococcal diseases and NTHi-related diseases vs. PCV-13, with a substantially greater reduction in NTHi-related AOM and a comparable reduction in IPD and community-acquired pneumonia. Parity-priced PHiD-CV generated a health gain of about 844 quality-adjusted life years and a total cost-saving of approximately 4 million United States Dollars (USD) over 10 y. 93% of probabilistic simulations found PHiD-CV 3+1 to be the dominant vaccine option.

CONCLUSION

Compared to PCV-13, PHiD-CV was projected to provide similar prevention against IPD and community-acquired pneumonia but would prevent more cases of AOM. Parity-priced PHiD-CV was anticipated to generate substantial cost-savings and health benefits vs. PCV-13 in Korea.

Authors+Show Affiliations

a GSK , Singapore.b Eclipse , Tervuren , Belgium.c GSK , Seoul , Korea.d IMS Health , Seoul , Korea.e Department of Family Medicine , The Catholic University, Seoul St. Mary Hospital , Seoul , Korea.

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29115905

Citation

Zhang, Xu-Hao, et al. "Cost-effectiveness Analysis of Infant Pneumococcal Vaccination With PHiD-CV in Korea." Human Vaccines & Immunotherapeutics, vol. 14, no. 1, 2018, pp. 85-94.
Zhang XH, Leeuwenkamp O, Oh KB, et al. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea. Hum Vaccin Immunother. 2018;14(1):85-94.
Zhang, X. H., Leeuwenkamp, O., Oh, K. B., Lee, Y. E., & Kim, C. M. (2018). Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea. Human Vaccines & Immunotherapeutics, 14(1), 85-94. https://doi.org/10.1080/21645515.2017.1362513
Zhang XH, et al. Cost-effectiveness Analysis of Infant Pneumococcal Vaccination With PHiD-CV in Korea. Hum Vaccin Immunother. 2018 01 2;14(1):85-94. PubMed PMID: 29115905.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea. AU - Zhang,Xu-Hao, AU - Leeuwenkamp,Oscar, AU - Oh,Kyu-Bin, AU - Lee,Young Eun, AU - Kim,Chul-Min, Y1 - 2017/11/08/ PY - 2017/11/9/pubmed PY - 2019/1/12/medline PY - 2017/11/9/entrez KW - Korea KW - PHiD-CV KW - cost-effectiveness KW - pneumococcal KW - vaccine SP - 85 EP - 94 JF - Human vaccines & immunotherapeutics JO - Hum Vaccin Immunother VL - 14 IS - 1 N2 - BACKGROUND: Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) can cause invasive pneumococcal diseases (IPD), pneumonia, and acute otitis media (AOM). Both the 10-valent pneumococcal NTHi protein D conjugate vaccine (PHiD-CV) and the 13-valent pneumococcal conjugate vaccine (PCV-13) are included in the National Immunization Program for infants in Korea. This study aimed to evaluate the cost-effectiveness of the 3+1 schedule of PHiD-CV versus that of PCV-13 for National Immunization Program in Korea. METHODS: A published Markov model was adapted to evaluate the cost-effectiveness of vaccinating the 2012 birth cohort with PHiD-CV vs. PCV-13 from the Korean government perspective over 10 y. Best available published data were used for epidemiology, vaccine efficacy and disutilities. Data on incidence and direct medical costs were taken from the national insurance claims database. Sensitivity analyses were conducted to explore the robustness of the results. RESULTS: PHiD-CV was projected to prevent an additional 195,262 cases of pneumococcal diseases and NTHi-related diseases vs. PCV-13, with a substantially greater reduction in NTHi-related AOM and a comparable reduction in IPD and community-acquired pneumonia. Parity-priced PHiD-CV generated a health gain of about 844 quality-adjusted life years and a total cost-saving of approximately 4 million United States Dollars (USD) over 10 y. 93% of probabilistic simulations found PHiD-CV 3+1 to be the dominant vaccine option. CONCLUSION: Compared to PCV-13, PHiD-CV was projected to provide similar prevention against IPD and community-acquired pneumonia but would prevent more cases of AOM. Parity-priced PHiD-CV was anticipated to generate substantial cost-savings and health benefits vs. PCV-13 in Korea. SN - 2164-554X UR - https://www.unboundmedicine.com/medline/citation/29115905/Cost_effectiveness_analysis_of_infant_pneumococcal_vaccination_with_PHiD_CV_in_Korea_ DB - PRIME DP - Unbound Medicine ER -